Your browser doesn't support javascript.
Coronavirus disease-2019: A review on the disease exacerbation via cytokine storm and concurrent management.
Sunkara, Haripriya; Dewan, Syed Masudur Rahman.
  • Sunkara H; Pharmacology Division, Center for Life Sciences Research, Dhaka, Bangladesh; Department of Pharmacy Practice, Vijaya Institute of Pharmaceutical Sciences for Women, Vijayawada, India.
  • Dewan SMR; Pharmacology Division, Center for Life Sciences Research, Dhaka, Bangladesh; Department of Pharmacy, Noakhali Science and Technology University, Noakhali, Chattogram, Bangladesh; Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan. Electronic address: gobeshok.d@gmail.com.
Int Immunopharmacol ; 99: 108049, 2021 Oct.
Article in English | MEDLINE | ID: covidwho-1347666
ABSTRACT
Setting up treatment strategies is the highest concern today to reduce the fatality of COVID-19. Due to a very new kind of virus attack, no specific treatment has been discovered to date. The most crucial way to dominate the disease severity is now the repurposing of drugs. In this review, we focused on the current treatment approaches targeting the crucial causative factors for the disease burden through cytokine storm or cytokine release syndrome. Several vaccines have been developed and have been applied already for prevention purposes, and several are on the way to be developed, although the effects and side effects are under observation. Presently, regulation of the immune response through intervention treatment methods has been adjusted on the basis of the COVID-19 severity stage and generally includes vaccines, immunotherapies including convalescent plasma and immunoglobulin treatment, monoclonal antibodies, cytokine therapy, complement inhibition, regenerative medicine, and repurposed anti-inflammatory and immune-regulatory drugs. Combination therapy is not acceptable in all respects because there is no concrete evidence in clinical trials or in vivo data. Target-specific drug therapies, such as inhibition of cytokine-producing signaling pathways, could be an excellent solution and thus reduce the severity of inflammation and disease severity. Therefore, gathering information about the mechanism of disease progression, possible goals, and drug efficacy of immune-based approaches to combat COVID-19 in the context of orderly review analysis is consequential.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Cytokine Release Syndrome / COVID-19 / COVID-19 Drug Treatment / Anti-Inflammatory Agents Type of study: Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Int Immunopharmacol Journal subject: Allergy and Immunology / Pharmacology Year: 2021 Document Type: Article Affiliation country: J.intimp.2021.108049

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Cytokine Release Syndrome / COVID-19 / COVID-19 Drug Treatment / Anti-Inflammatory Agents Type of study: Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Int Immunopharmacol Journal subject: Allergy and Immunology / Pharmacology Year: 2021 Document Type: Article Affiliation country: J.intimp.2021.108049